/Companies

CHARM Therapeutics

London · Founded 2021 · 31 employees on LinkedIn · 8 known investors

Find your way into CHARM Therapeutics

Sign up to see every warm intro you have to CHARM Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the CHARM Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches. It applies AI and structure-based drug discovery to design potent inhibitors targeting protein-ligand interactions at the KMT2A interface on menin.

Founders & leadership

CHARM Therapeutics was founded in 2021 by Lakshyaditya Singh Aithani.

LS
Lakshyaditya Singh AithaniFounder
DB
David BakerFounder
LA
Laksh AithaniFounder

Board

RGRishi Gupta
Rishi GuptaBoard MemberPartner at OrbiMed
NSNihal Sinha
Nihal SinhaBoard Director, Founding InvestorPartner at F-Prime Capital Partners
MMMuzammil Mansuri
Muzammil MansuriBoard directorAdvisor at Delin Ventures
GGGary Glick
Gary GlickExecutive ChairmanExecutive Officer, Director at Scorpion Therapeutics

Investors · 8

Reported raises · per SEC filings

Form D private placements

$87M disclosed across 4 rounds · 2021–2025

▶$17.3MraisedSep 2025 · 20 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Gary GlickExecutive Officer, Director, Promoter
  • Mahesh KudariDirector
  • Briggs MorrisonDirector
  • Nihal SinhaDirector
  • Kim BlackwellDirector
  • Matthew McAvineyDirector
  • Rishi GuptaDirector
Offering amount
$80.1M
Amount sold
$17.3M
First sale
Aug 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20MraisedApr 2023 · 2 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Gary GlickDirector
  • Lakshyaditya Singh AithaniExecutive Officer, Director
  • Nihal SinhaDirector
  • Muzammil MansuriDirector
  • Rishi GuptaDirector
Offering amount
$20M
Amount sold
$20M
First sale
Apr 2023
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$37MraisedJun 2022 · 18 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Gary GlickDirector
  • Rishi GuptaDirector
  • Nihal SinhaDirector
  • Lakshyaditya Singh AithaniExecutive Officer, Director
  • Muzammil MansuriDirector
Offering amount
$37M
Amount sold
$37M
First sale
Apr 2022
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.6MraisedOct 2021 · 8 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Lakshyaditya Singh AithaniExecutive Officer, Director, Promoter
Offering amount
$13.5M
Amount sold
$12.6M
First sale
Oct 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does CHARM Therapeutics do?
CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches. It applies AI and structure-based drug discovery to design potent inhibitors targeting protein-ligand interactions at the KMT2A interface on menin.
Who founded CHARM Therapeutics?
CHARM Therapeutics was founded by Lakshyaditya Singh Aithani in 2021.
Who are CHARM Therapeutics's investors?
CHARM Therapeutics's investors include F-Prime Capital, New Enterprise Associates (NEA), NVIDIA, OrbiMed, SR One Capital Management, Axial VC, Khosla Ventures, NVentures.
How much funding has CHARM Therapeutics raised?
CHARM Therapeutics has disclosed $87M raised across 4 rounds.
Where is CHARM Therapeutics headquartered?
CHARM Therapeutics is headquartered in London.